Get the Stockscreener App
10.38
2.90%
-0.31
After Hours:
10.38
Meiragtx Holdings Plc stock is traded at $10.38, with a volume of 506.50K.
It is down -2.90% in the last 24 hours and down -18.84% over the past month.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
See More
Previous Close:
$10.69
Open:
$10.69
24h Volume:
506.50K
Relative Volume:
0.49
Market Cap:
$996.93M
Revenue:
$79.76M
Net Income/Loss:
$-120.53M
P/E Ratio:
-6.9711
EPS:
-1.489
Net Cash Flow:
$3.75M
1W Performance:
-4.95%
1M Performance:
-18.84%
6M Performance:
+15.72%
1Y Performance:
+32.40%
1-Day Range:
$10.32
$10.76
1-Week Range:
$10.32
$11.01
52-Week Range:
$6.62
$15.35
Meiragtx Holdings Plc Stock (MGTX) Company Profile
Name
Meiragtx Holdings Plc
Sector
Industry
Phone
646-860-7985
Address
655 THIRD AVENUE, NEW YORK, NY
Compare MGTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGTX
Meiragtx Holdings Plc
|
10.38 | 996.93M | 79.76M | -120.53M | 3.75M | -1.489 |
VRTX
Vertex Pharmaceuticals Inc
|
507.00 | 128.50B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
213.74 | 85.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
762.81 | 78.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.30 | 51.08B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.95 | 41.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Meiragtx Holdings Plc Stock (MGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-26 | Initiated | Goldman | Neutral |
| Nov-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-21-25 | Initiated | Raymond James | Strong Buy |
| Jul-31-24 | Resumed | Chardan Capital Markets | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Sep-15-20 | Resumed | BofA Securities | Buy |
| Sep-03-19 | Initiated | Piper Jaffray | Overweight |
| Feb-27-19 | Reiterated | Chardan Capital Markets | Buy |
| Jul-03-18 | Initiated | Barclays | Overweight |
| Jul-03-18 | Initiated | BofA/Merrill | Buy |
View All
Meiragtx Holdings Plc Stock (MGTX) Latest News
Meiragtx chief scientific officer sells $294,291 in stock By Investing.com - Investing.com UK
Officer Stuart Naylor proposes selling 27,659 MeiraGTx (NASDAQ: MGTX) shares worth $294K. - Stock Titan
A 100,000-unit share award for MeiraGTx (MGTX) director Alan Sebulsky vests over three years. - Stock Titan
MeiraGTx (MGTX) director Alan Sebulsky reports shares held through an LLC he manages. - Stock Titan
MeiraGTx Holdings PLC Share PriceMGTX, RNS News, Articles, Quotes, & Charts - Proactive financial news
Responsive Playbooks and the MGTX Inflection - Stock Traders Daily
Meiragtx Holdings Stock Price Forecast. Should You Buy MGTX? - StockInvest.us
MeiraGTx Holdings (MGTX) Q2 2026 Earnings: Massive EPS Beat Driven by Non-Operating Items, Stock Still SlipsRevenue Per Share - siam.in
MeiraGTx Holdings (MGTX) Q2 2026 Earnings: Massive EPS Beat Driven by Non-Operating Items, Stock Still Slips - dars.gov.et
MeiraGTx (MGTX) Slips 2.89% to $13.78 as Gene-Therapy Stock Approaches SupportJelly Roll Trade - vinanet.vn
Regencell Bioscience Holdings Ltd (RGC) Peer Comparison – Compare with Others - Value Research
MeiraGTx (MGTX) Results at a Glance: Reported EPS Misses Expectations under the Current Snapshot; Closing Move - careplusvn.com
Why MeiraGTx (MGTX) Is Up 7.7% After Swing to Q2 Profitability and New Leadership Hires - simplywall.st
MeiraGTx (MGTX) Earnings Reading: Profit Per Share Falls Below Its Benchmark in the Reported Period; Closing Move - vinanet.vn
MeiraGTx (MGTX) Earnings Reading: Profit Per Share Falls Below Its Benchmark in the Reported Period; Closing Move: The Stock Records a 1.05% Decrease in the Available RecordEarnings Call Q&A - careplusvn.com
MeiraGTx (MGTX) Earnings Reading: Profit Per Share Falls Below Its Benchmark in the Reported Period; Closing Move - dars.gov.et
MeiraGTx (NASDAQ:MGTX) Clears Minervini Trend Template and High-Growth Momentum Screen - ChartMill
Tocqueville Asset Management L.P. Makes New $1.05 Million Investment in MeiraGTx Holdings PLC $MGTX - MarketBeat
MeiraGTx CEO Alexandria Forbes sells 62,000 shares for $859,320 - Bitget
Meiragtx CEO Forbes sells $859,320 in company stock By Investing.com - Investing.com Australia
Meiragtx CEO Forbes sells $859,320 in company stock By Investing.com - Investing.com Australia
Alexandria Forbes Sells 62,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock - MarketBeat
Meiragtx CEO Forbes sells $859,320 in company stock - Investing.com
Meiragtx CEO Forbes sells $859,320 in company stock By Investing.com - Investing.com South Africa
Meiragtx CEO Forbes sells $859,320 in company stock By Investing.com - Investing.com Nigeria
Meiragtx CEO Forbes sells $859,320 in company stock By Investing.com - Investing.com UK
Meiragtx CEO Forbes sells $859,320 in company stock - Investing.com
MeiraGTx (MGTX) holder readies new sale after recent 62K-share cashout - Stock Titan
MeiraGTx (MGTX) CEO sells 62K shares in preset plan at $13.86 - stocktitan.net
MeiraGTx (MGTX) Q1 2026 Results: Profit Per Share Falls Below Its Benchmark under the Current Snapshot - vinanet.vn
MeiraGTx (MGTX) Q1 2026 Results: Profit Per Share Falls Below Its Benchmark under the Current Snapshot - careplusvn.com
MeiraGTx (MGTX) Q1 2026 Results: Profit Per Share Falls Below Its Benchmark under the Current Snapshot; Reported Share Move: Shares Move Higher 0.22% on the DayEarnings Turnaround - dars.gov.et
MeiraGTx (MGTX) Q1 2026 Results: Profit Per Share Falls Below Its Benchmark under the Current Snapshot; Reported Share Move: Shares Move Higher 0.22% on the DayPretax Income Report - dars.gov.et
FY2026 EPS Estimates for MeiraGTx Increased by HC Wainwright - MarketBeat
MeiraGTx (MGTX) Jumps 6.7% to $13.52 as Gene Therapy Pipeline Optimism GrowsWeak Sell Signals - vinanet.vn
Johnson & Johnson Takes $89.72 Billion Position in MeiraGTx Holdings PLC $MGTX - MarketBeat
Price-Driven Insight from (MGTX) for Rule-Based Strategy - Stock Traders Daily
Profit Surge and New Leadership Might Change The Case For Investing In MeiraGTx Holdings (MGTX) - simplywall.st
Profit Surge and New Leadership Might Change The Case For Investing In MeiraGTx Holdings (MGTX) - simplywall.st
MeiraGTx (NASDAQ:MGTX) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
MeiraGTx (NASDAQ:MGTX) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
What Could MeiraGTx Holdings (MGTX) New Hires And Profit Swing Signal? - Yahoo Finance
Rubric Capital discloses 9.83% MeiraGTx (MGTX) position totaling 9.1M shares - Stock Titan
MeiraGTx (NASDAQ:MGTX) Trading 8.4% Higher Following Strong Earnings - MarketBeat
MGTX Maintains by RBC Capital -- Price Target Raised to $27.00 - GuruFocus
MeiraGTx Seen Nearing First Commercial Launches as Key Programs Advance, RBC Says - marketscreener.com
MeiraGTx (NASDAQ:MGTX) Given New $27.00 Price Target at Royal Bank Of Canada - marketbeat.com
MeiraGTx (MGTX) Gains 4.42% as Gene Therapy Focus Draws Investor AttentionETF Inflow Streak - vinanet.vn
RBC Adjusts PT on MeiraGTx to $27 From $26, Maintains Outperform Speculative Risk Rating - marketscreener.com
Sei Investments Co. Buys Shares of 99,627 MeiraGTx Holdings PLC $MGTX - MarketBeat
Meiragtx Holdings Plc Stock (MGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Meiragtx Holdings Plc Stock (MGTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Naylor Stuart | Officer |
Oct 06 '26 |
Proposed Sale |
10.64 |
27,659 |
294,321 |
0 |
| Alexandria Forbes | Officer |
Aug 18 '26 |
Proposed Sale |
13.86 |
62,000 |
859,320 |
0 |
| Forbes Alexandria | PRESIDENT & CEO |
Aug 18 '26 |
Sale |
13.86 |
62,000 |
859,320 |
1,325,695 |
| Richard Giroux | Officer |
Jul 21 '26 |
Proposed Sale |
12.51 |
56,000 |
700,560 |
0 |
| Giroux Richard | CFO & COO |
Jul 21 '26 |
Sale |
12.51 |
56,000 |
700,560 |
908,530 |
| Naylor Stuart | CHIEF SCI OFCR, OPHTHALMOLOGY |
Jul 07 '26 |
Sale |
14.80 |
27,659 |
409,470 |
640,846 |
| Naylor Stuart | Officer |
Jul 07 '26 |
Proposed Sale |
13.33 |
27,659 |
368,694 |
0 |
| Forbes Alexandria | PRESIDENT & CEO |
May 19 '26 |
Sale |
9.17 |
62,000 |
568,540 |
1,387,695 |
| Alexandria Forbes | Officer |
May 19 '26 |
Proposed Sale |
9.17 |
62,000 |
568,540 |
0 |
| Richard Giroux | Officer |
Apr 21 '26 |
Proposed Sale |
10.22 |
56,000 |
572,545 |
0 |
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):